Replies to post #143919 on Biotech Values

[DewDiligence]

Well, NICE is not the standard we should be looking at…

I disagree—NICE is indeed the standard investors should be watching because the world is moving in that direction. That’s the whole problem.

[DewDiligence]

More on “creative” (translation: low) drug prices in Europe:

http://www.reuters.com/article/2012/10/24/us-pharmaceuticals-europe-pricing-idUSBRE89N0GQ20121024

Many of today's complicated pricing arrangements have their origins in pioneering work by Britain's National Institute for Health and Clinical Excellence (NICE), which was set up in 1999 to systematically assess the cost-effectiveness of new drugs.

... Cancer drugs are a major focus, reflecting the dilemma posed by costly new treatments that may help some patients but often only extend life by only a few months.

[DewDiligence]

[NICE] are going to apply their made-up standards to expensive drugs in any class - not just oncology.

However, oncology is clearly a focus, as the previous post (#msg-80856836) points out. (Ditto for the US market—see #msg-80599468.)

I stand by the assertion in #msg-76636562 where I said, “NICE is indeed the standard investors should be watching because the world is moving in that direction.”

Most biotech investors who concentrate on oncology are going to end up with bad track records during the next decade, IMHO.